“Rising Adoption in Clinical Diagnostics”
The rising adoption of mass spectrometry in clinical diagnostics is driven by its ability to analyze complex biological samples, advancing personalized medicine and disease diagnostics. In proteomics, it identifies and quantifies proteins linked to diseases like cancer, while in metabolomics, it profiles metabolic changes associated with conditions such as diabetes and neurodegenerative disorders. Mass spectrometry also plays a key role in biomarker discovery, enabling the identification of molecules that signal the presence or progression of diseases, supporting early and accurate diagnosis. This technology enhances personalized treatment by helping tailor therapies to a patient’s unique biological profile and is advancing non-invasive diagnostics through the analysis of fluids like breath, urine, or saliva, improving patient comfort and compliance.
